In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Table 5 Pregnancy outcomes - all patients

Characteristic	rFSH	hMG-HP	Chi-square	p-value
Total cycles started	22665	7965
Number (%) of total cycles with oocytes retrieved	22,467 (99.13%)	7,958 (99.91%)	54.73	<0.0001
Cycles (%) with positive pregnancy test as percent of cycles started	7595 (33.53%)	2553 (32.05)	5.72	0.0168
Cycles (%) with positive pregnancy test as percent of cycles with oocyte retrieved	7595 (33.81% per ET)	2551 (32.06% per ET)	8.09	0.0044
Any clinical pregnancy as percent of cycles with oocyte retrieved	7423 (33.04)	2550 (32.04)	56.43	0.1037
Pregnancies ending in spontaneous abortion as percent of cycles with oocyte retrieved^†	1303 (6.16%)	478 (6.02%)	0.19	0.6625

Note: Cycles with positive pregnancy test were defined as cycles with a biochemical pregnancy and any clinical pregnancy. Clinical pregnancies were defined based on data entries 'clinical pregnancy', 'ongoing pregnancy', 'live birth', and 'spontaneous abortion'. Pregnancies ending in spontaneous abortion were defined as those with data entries 'spontaneous abortion' and 'miscarriage'. ^† Due to lack of data on this outcome, only data for Germany and Denmark were considered here to calculate the percentage (N = 21,160 for rFSH subgroup; N = 7,940 for hMG-HP subgroup).

ISSN: 1477-7827